Other relevant Publications

/Other relevant Publications
Other relevant Publications 2018-12-03T09:51:42+00:00

2018

2017

  • Sulaiman I, Seheult J, Sadasivuni N, MacHale E, Killane I, Giannoutsos S, Cushen B, Mokoka MC, Bhreathnach AS, Boland F, Reilly RB, Costello RW. The Impact of Common Inhaler Errors on Drug Delivery: Investigating Critical Errors with a Dry Powder Inhaler. J Aerosol Med Pulm Drug Deliv. 2017 Aug;30(4):247-255.
    Http://dx.doi.org/10.1089/jamp.2016.1334
  • Molimard M, Raherison C, Lignot S, Balestra A, Lamarque S, Chartier A, Droz-Perroteau C, Lassalle R, Moore N, Girodet PO. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J. 2017 Feb 15;49(2)
    Http://dx.doi.org/10.1183/13993003.01794-2016

2016

2015

  • Azouz W, Chetcuti P, Hosker HS, Saralaya D, Stephenson J, Chrystyn H. The inhalation characteristics of patients when they use different dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2015 Feb;28(1):35-42.
    Http://dx.doi.org/10.1089/jamp.2013.1119
  • Scichilone N, Benfante A, Bocchino M, Braido F, Paggiaro P, Papi A, Santus P, Sanduzzi A. Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases? Pulm Pharmacol Ther. 2015 Feb 24.
    Http://dx.doi.org/10.1016/j.pupt.2015.02.006
  • Van Aalderen WM, Garcia-Marcos L, Gappa M, Lenney W, Pedersen S, Dekhuijzen R, Price D. How to match the optimal currently available inhaler device to an individual child with asthma or recurrent wheeze. NPJ Prim Care Respir Med. 2015 Jan 8;25:14088.
    Http://dx.doi.org/10.1038/npjpcrm.2014.88
  • Leaker BR, Barnes PJ, Jones CR, Tutuncu A, Singh D. Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease. Br J Clin Pharmacol. 2015 Mar;79(3):492-500.
    Http://dx.doi.org/10.1111/bcp.12517

2014

  • Molimard M, Colthorpe P. Inhaler Devices for Chronic Obstructive Pulmonary Disease: Insights from Patients and Healthcare Practitioners. J Aerosol Med Pulm Drug Deliv. 2014 Sep 29.
    Http://dx.doi.org/10.1089/jamp.2014.1142
  • Chrystyn H, Small M, Milligan G, Higgins V, Gil EG, Estruch J. Impact of patients’ satisfaction with their inhalers on treatment compliance and health status in COPD. Respir Med. 2014 Feb;108(2):358-65.
    Http://dx.doi.org/10.1016/j.rmed.2013.09.021
  • Corradi M, Chrystyn H, Cosio BG, Pirozynski M, Loukides S, Louis R, Spinola M, Usmani OS. NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma. Expert Opin Drug Deliv. 2014 Sep;11(9):1497-506.
    Http://dx.doi.org/10.1517/17425247.2014.928282
  • Aggarwal B, Gogtay J. Use of pressurized metered dose inhalers in patients with chronic obstructive pulmonary disease: review of evidence. Expert Rev Respir Med. 2014 Jun;8(3):349-56.
    Http://dx.doi.org/10.1586/17476348.2014.905916
  • Vogelmeier C, Kardos P, Hofmann T, Canisius S, Scheuch G, Muellinger B, Nocker K, Menz G, Rabe KF. Nebulised budesonide using a novel device in patients with oral steroid-dependent asthma. Eur Respir J. 2014 Dec 10.
    Http://dx.doi.org/10.1183/09031936.00152014
  • Chawes BL, Govoni M, Kreiner-Møller E, Vissing NH, Poorisrisak P, Mortensen L, Nilsson E, Bisgaard A, Dossing A, Deleuran M, Skytt NL, Samandari N, Piccinno A, Sergio F, Ciurlia G, Poli G, Acerbi D, Singh D, Bisgaard H. Systemic exposure to inhaled beclometasone/formoterol DPI is age and body size dependent. Respir Med. 2014 Aug;108(8):1108-16.
    Http://dx.doi.org/10.1016/j.rmed.2014.05.007
  • Ninane V, Brusselle GG, Louis R, Dupont L, Liistro G, De Backer W, Schlesser M, Vincken W. Usage of inhalation devices in asthma and chronic obstructive pulmonary disease: a Delphi consensus statement. Expert Opin Drug Deliv. 2014 Mar;11(3):313-23.
    Http://dx.doi.org/10.1517/17425247.2014.872626

2013

  • Smaldone G, Berkland C, Gonda I, Mitchell J, Usmani OS, Clark A. Ask the experts: the benefits and challenges of pulmonary drug delivery. Ther Deliv. 2013;4(8):905-13.
    Http://dx.doi.org/10.4155/tde.13.76
  • Lavorini F, Ninane V, Haughney J, Bjermer L, Molimard M, Dekhuijzen RP. Switching from branded to generic inhaled medications: potential impact on asthma and COPD. Expert Opin Drug Deliv. 2013;10(12):1597-602.
    Http://dx.doi.org/10.1517/17425247.2013.852182
  • Colthorpe P, Voshaar T, Kieckbusch T, Cuoghi E, Jauernig J. Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the longacting muscarinic antagonist glycopyrronium. J Drug Assess 2013;2:11-6.
    Http://dx.doi.org/10.3109/21556660.2013.766197
  • Dekhuijzen PNR, Vincken W, Virchow JC, Roche N, Agusti A, Lavorini F, Van Aalderen WM, Price D. Prescription of inhalers in asthma and COPD: towards a rational, rapid and effective approach. Respir Med. 2013 Dec;107(12):1817-21.
    Http://dx.doi.org/10.1016/j.rmed.2013.09.013

2012

  • Capstick TG1, Clifton IJ. Inhaler technique and training in people with chronic obstructive pulmonary disease and asthma. Expert Rev Respir Med. 2012;6(1):91-101;
    Http://dx.doi.org/10.1586/ers.11.89
  • Price D, Chrystyn H, Kaplan A, Haughney J, Román-Rodríguez M, Burden A, Chisholm A, Hillyer EV, von Ziegenweidt J, Ali M, van der Molen T. Effectiveness of same versus mixed asthma inhaler devices: a retrospective observational study in primary care. Allergy Asthma Immunol Res. 2012;4(4):184-91.
    Http://dx.doi.org/10.4168/aair.2012.4.4.184
  • Plaza V, Sanchis J, Roura P, Molina J, Calle M, Quirce S, Viejo JL, Caballero F, Murio C. Physicians’ knowledge of inhaler devices and inhalation techniques remains poor in Spain. J Aerosol Med Pulm Drug Deliv. 2012;25(1):16-22.
    Http://dx.doi.org/10.1089/jamp.2011.0895

2011

  • Laube BL, Janssens HM, de Jongh FH, Devadason SG, Dhand R, Diot P, Everard ML, Horvath I, Navalesi P, Voshaar T, Chrystyn H; European Respiratory Society; International Society for Aerosols in Medicine. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011;37:1308-31.
    Http://dx.doi.org/10.1183/09031936.00166410
  • Hardwell A, Barber V, Hargadon T, McKnight E, Holmes J, Levy ML. Technique training does not improve the ability of most patients to use pressurised metered-dose inhalers (pMDIs). Prim Care Respir J. 2011;20(1):92-6.
    Http://dx.doi.org/10.4104/pcrj.2010.00088
  • Dalby RN, Eicher J, Zierenberg B. Development of Respimat® Soft MistTM inhaler and its clinical utility in respiratory disorders. Med Devices Auckl 2011;4:145-55.
    Http://dx.doi.org/10.2147/MDER.S7409

2010

  • De Backer W, Devolder A, Poli G, Acerbi D, Monno R, Herpich C, Sommerer K, Meyer T, Mariotti F. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv. 2010;23(3):137-48.
    Http://dx.doi.org/10.1089/jamp.2009.0772
  • Doyle S, Lloyd A, Williams A, Chrystyn H, Moffat M, Thomas M, Price D. What happens to patients who have their asthma device switched without their consent? Prim Care Respir J. 2010;19(2):131-9.
    Http://dx.doi.org/10.4104/pcrj.2010.00009